Satsuma Pharmaceuticals, Inc.
NASDAQ: STSA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John A. Kollins MBA
- Employees
- 25
- Headquarters
- South San Francisco, United States
- IPO year
- 2019
- Market cap
- $36.5M
- Website
- https://www.satsumarx.com
Loading STSA…
Loading profile data…Frequently asked questions about STSA
What does Satsuma Pharmaceuticals, Inc. (STSA) do?
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing throug...
Where does STSA trade?
Satsuma Pharmaceuticals, Inc. (STSA) trades on the NASDAQ Global Market.
What sector is STSA in?
Satsuma Pharmaceuticals, Inc. (STSA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Satsuma Pharmaceuticals, Inc.?
John A. Kollins MBA is the chief executive officer of Satsuma Pharmaceuticals, Inc. (STSA).
Where is Satsuma Pharmaceuticals, Inc. headquartered?
Satsuma Pharmaceuticals, Inc. is headquartered in United States.
Does STSA pay a dividend?
Yes — Satsuma Pharmaceuticals, Inc. (STSA) paid a trailing twelve-month dividend of USD 1.50 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did STSA go public?
Satsuma Pharmaceuticals, Inc. (STSA) completed its initial public offering in 2019.